Session Information
Date: Tuesday, September 24, 2019
Session Title: Parkinsonisms and Parkinson-Plus
Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: To leverage technology to develop a new model for the long-term follow-up of Parkinson’s disease (PD) clinical trial cohorts and investigate novel disease measures.
Background: Long-term follow-up of early PD clinical trial cohorts may generate novel insights about disease progression and heterogeneity. However, infrastructure, personnel, and financial demands render multi-year in-person follow-up studies infeasible.
Method: AT-HOME PD is a 24-month, remote observational follow-up study of two multi-center phase 3 clinical trials of potential disease-modifying therapeutics for PD (STEADY-PDIII and SURE-PD3) with three platforms: virtual research visits (real-time videoconferencing), mPower 2.0 smartphone application, and Fox Insight (an online survey-based clinical research study). Data from the three platforms is deposited and aggregated in Synapse, a cloud-based data management and research collaboration platform, and then transferred to the Parkinson’s Disease Biomarkers Program’s (PDBP) Data Management Resource, where it will be integrated with data from STEADY-PDIII and SURE-PD3 and made available to the broader research community.
Results: 262/336 (78%) STEADY-PDIII and 234/298 (79%) SURE-PD3 participants have agreed to be contacted regarding participation in AT-HOME PD. We have conducted 208 screening visits and 192 baseline visits for participants located in 40 U.S states and Canada. 147 (77%) are participating in Fox Insight and 152 (79%) are participating in mPower 2.0. Whole genome sequencing of DNA from over 90% of the parent study participants has been initiated through the Accelerated Medicine Partnership-PD (AMP-PD) and PDBP programs, and is expected to enhance analysis of genetic determinants of AHPD tele-health outcomes.
Conclusion: Over 9 months, we have enrolled approximately 30% of STEADY-PDIII and SURE-PD3 participants into AT-HOME PD. Recruitment may have been hampered by the delayed initiation of AT-HOME PD relative to the conclusion of STEADY-PDIII and SURE-PD3 study visits and negative results of the parent studies.
To cite this abstract in AMA style:
R. Schneider, L. Omberg, T. Myers, S. Anthwal, E. Kayson, C. Tarolli, M. Daeschler, E. Macklin, E. Dorsey, L. Mangravite, M. Schwarzschild, T. Simuni. Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease Trials (AT-HOME PD): An Update on Recruitment [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/assessing-tele-health-outcomes-in-multiyear-extensions-of-parkinsons-disease-trials-at-home-pd-an-update-on-recruitment/. Accessed May 21, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/assessing-tele-health-outcomes-in-multiyear-extensions-of-parkinsons-disease-trials-at-home-pd-an-update-on-recruitment/